Sugi Predict

Sugi Predict / Compounds / SCHEMBL534247

SCHEMBL534247

SCHEMBL534247

CC(C)(C)c1cccc(Br)n1

nearest known ligand 0.35

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ HTR7 P34969 2/20 0.35
▸ HTR1A P08908 1/20 0.35
▸ DRD2 P14416 1/20 0.35
▸ HTR2A P28223 1/20 0.35
▸ SYK P43405 1/20 0.33
▸ CYP3A4 P08684 1/20 0.32
▸ TSHR P16473 1/20 0.32
▸ CCR4 P51679 6/20 0.32
▸ GRM5 P41594 1/20 0.32
▸ IRAK4 Q9NWZ3 1/20 0.31
▸ GABRA1 P14867 1/20 0.31
▸ GABRG2 P18507 1/20 0.31
▸ GABRB3 P28472 1/20 0.31
▸ GABRA3 P34903 1/20 0.31
▸ CA2 P00918 1/20 0.31
▸ CTH P32929 1/20 0.30
▸ ALDH1A1 P00352 1/20 0.30
▸ LMNA P02545 1/20 0.30
▸ GAA P10253 1/20 0.30
▸ IDH1 O75874 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29427057 1.00 HTR7 (0.35) HTR7HTR1ADRD2HTR2ASYK
SCHEMBL1960610 0.88 SMN1; SMN2 (0.35) HTR7HTR1ADRD2HTR2ASYK
SCHEMBL2757632 0.86 HTR7 (0.35) HTR7HTR1ADRD2HTR2ACYP3A4
SCHEMBL9007757 0.83 HTR7 (0.35) HTR7HTR1ADRD2HTR2AIRAK4
SCHEMBL5646151 0.82 GABRA1 (0.36) HTR7HTR1ADRD2HTR2ACYP3A4
SCHEMBL906585 0.82 CTH (0.35) HTR7HTR1ADRD2HTR2ASYK
SCHEMBL31078226 0.82 IDH1 (0.37) HTR7HTR1ADRD2HTR2ACYP3A4
SCHEMBL1041388 0.82 HTR7 (0.33) HTR7HTR1ADRD2HTR2ACYP3A4
SCHEMBL1111062 0.82 IRAK4 (0.33) HTR7HTR1ADRD2HTR2ACYP3A4
SCHEMBL29444546 0.82 CTH (0.35) HTR7HTR1ADRD2HTR2ASYK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 191 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-122079879-A Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof — 2026-05-26 — — CN disclosed
CN-122079878-A Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof — 2026-05-26 — — CN disclosed
CN-120476110-B Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof SHANGHAI HANSOH BIOMEDICAL Co.,Ltd. (CN) 2026-05-26 — — CN disclosed
CN-122079880-A Nitrogen-containing heterocyclic derivative inhibitor, preparation method and application thereof — 2026-05-26 — — CN disclosed
CN-117659017-B TRPML1/2 modulator compound, pharmaceutical composition, preparation method and application thereof 北京华益健康药物研究中心 2026-05-15 — — CN disclosed
EP-4741376-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF Shanghai Hansoh Biomedical Co., Ltd. (CN) 2026-05-13 — — EP disclosed
US-12612403-B2 Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof SHANGHAI HANSOH BIOMEDICAL CO., LTD. (CN) 2026-04-28 — — US disclosed
US-20260085045-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF SHANGHAI HANSOH BIOMEDICAL CO LTD (CN) 2026-03-26 — — US disclosed
EP-4103557-B1 MONOACYLGLYCEROL LIPASE MODULATORS JANSSEN PHARMACEUTICA NV (BE) 2026-02-18 — — EP disclosed
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2026-02-12 — — US disclosed
US-20070167443-A1 Substituted quinolones and methods of use CHEMOCENTRYX, INC. (US) 2007-07-19 — — US disclosed
US-20050107388-A1 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain MERCK SHARP & DOHME LTD. (GB) 2005-05-19 — — US disclosed
EP-1490340-A1 HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN MERCK SHARP & DOHME LTD. (GB) 2004-12-29 — — EP disclosed
WO-2003080578-A1 HETEROAROMATIC UREA DERIVATIVES AS VR-1 RECEPTOR MODULATORS FOR TREATING PAIN MERCK SHARP & DOHME LIMITED (GB) 2003-10-02 — — WO disclosed
CN-1089338-C Pyridine derivatives as fungicides ZENECA LTD (GB) 2002-08-21 — — CN disclosed
US-6169101-B1 FUNGICIDES ZENECA LIMITED (GB) 2001-01-02 — — US disclosed
EP-0882019-B1 PYRIDINE DERIVATIVES AS FUNGICIDES ZENECA LTD (GB) 2000-07-05 — — EP disclosed
CN-1210519-A Pyridine derivatives as fungicides ZENECA LTD (GB) 1999-03-10 — — CN disclosed
EP-0882019-A1 PYRIDINE DERIVATIVES AS FUNGICIDES ZENECA LIMITED (GB) 1998-12-09 — — EP disclosed
WO-1997029088-A1 PYRIDINE DERIVATIVES AS FUNGICIDES ZENECA LIMITED (GB) 1997-08-14 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12612403-B2 Nitrogen-containing heterocyclic derivative inhibitor, and preparation method therefor and use thereof FAR1, NPR1, CBR1 HTR7 243/4885HTR1A 711/4885DRD2 1548/4885
US-20070167443-A1 Substituted quinolones and methods of use TOP2A, NQO2, TOP2B HTR7 1250/4885HTR1A 2640/4885DRD2 3942/4885
US-20260042749-A1 IRAK DEGRADERS AND USES THEREOF IRAK2, IRAK3, IRAK4 HTR7 2606/4885HTR1A 2758/4885DRD2 2318/4885
US-20050107388-A1 Heteroaromatic urea derivatives as vr-1receptor modulators for treating pain ARRB1, OPRL1, CNR1 HTR7 395/4885HTR1A 121/4885DRD2 196/4885
US-20260085045-A1 NITROGEN-CONTAINING HETEROCYCLIC DERIVATIVE INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF NPR1, CBR1, NAT1 HTR7 336/4885HTR1A 355/4885DRD2 1625/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.